Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Lu, Liangjun, Pilot-Matias, Tami J., Stewart, Kent D., Randolph, John T., Pithawalla, Ron, He, Wenping, Huang, Peggy P., Klein, Larry L., Mo, Hongmei, Molla, Akhteruzzaman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2004
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!